Celebrex celecoxib COX-2 inhibitor regulatory update

The FDA's Oncologic Drugs Advisory Committee voted 14-0 with one abstention to recommend approval of Celebrex as an adjunct to standard of care to reduce and regress adenomatous colorectal polyps in p...